600+


Publications

4,000+


Impact factors

2,200+


Clinical Projects

HIGHLIGHTED STUDIES FOR CANCER EARLY DETECTION


HIGHLIGHTED STUDIES FOR MINIMAL RESIDUAL DISEASE TRACKING


OTHER HIGHLIGHTED STUDIES


  1. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics. Cancer Research Communications. 2023 May 16. doi.org/10.1158 /2767-9764.CRC-22-0363
  2. Tumor-naïve circulating tumor DNA as an early response biomarker for patients treated with immunotherapy in early phase clinical trials. JCO Precision Oncology. 2023 Apr;7:e2200509. doi: 10.1200/PO.22.00509.
  3. Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications. 2021 November 8; 12, 6454. doi:10.1038/s41467-021-26806-7
  4. Timing and origins of local and distant metastases in lung cancer. Journal of Thoracic Oncology. 2021 Mar 12. doi:10.1016/j.jtho.2021.02.023
  5. Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the Apollo study. Clinical Cancer Research. 2020 Dec 1;26(23):6168-6175. doi: 10.1158/1078-0432.CCR-20-2081.
  6. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters. 2020 Mar 1;472:108-118. doi: 10.1016/j.canlet.2019.12.004.
  7. Distribution of NRG1 gene fusions in a large population of Chinese patients with NSCLC. Journal of Thoracic Oncology. 2019 Dec;14(12):e263-e266. doi: 10.1016/j.jtho.2019.07.012.
  8. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small-cell lung cancer. Clinical Cancer Research. 2019 Aug 15;25(16):5015-5026. doi: 10.1158/1078-0432.CCR-19-0585.
  9. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019 Jul 28;9(19):5532-5541. doi: 10.7150/thno.34070.
  10. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152-1161. doi: 10.1136/gutjnl-2018-316522.
  11. Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica. 2019 May;104(5):e195-e199. doi: 10.3324/haematol.2018.205369.
  12. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.
  13. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019 Jan 1;142(1):23-34. doi: 10.1093/brain/awy307
  14. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. Clinical Cancer Research. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310.
  15. Circulating tumor DNA mutational profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Scientific Reports. 2017 Apr 3;7(1):583. doi: 10.1038/s41598-017-00520-1.
  16. The unique characteristics of MET Exon 14 mutation in Chinese patients with NSCLC. Journal of Thoracic Oncology. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016.